Author

Joshua T. Myers

Observed names: Joshua Myers, Joshua T Myers

Institution: Rani Therapeutics (United States)

Observed institution: Rani Therapeutics (United States)

ORCID: 0009-0002-1467-6282

Observed ORCID: 0009-0002-1467-6282

OpenAlex ID: A5048799109

Preference for a Novel Oral Alternative to Parenterally Administered Medications

2024 · Joshua Myers, Jacques Van Dam, et al. · Patient Preference and Adherence · 39

An oral robotic pill reliably and safely delivers teriparatide with high bioavailability in healthy volunteers: A phase 1 study

2025 · Joshua T. Myers, Alyson Yamaguchi, et al. · British Journal of Clinical Pharmacology · 6

Oral delivery of an ustekinumab biosimilar with bioavailability comparable to subcutaneous administration in healthy human participants

2026 · Joshua T. Myers, Alyson Yamaguchi, et al. · European Journal of Clinical Pharmacology · 2

An Orally Administered Robotic Pill (rp) Reliably and Safely Delivers an Ustekinumab Biosimilar With High Bioavailability Relative to Subcutaneous (sc) Ustekinumab in Healthy Human Participants

2024 · Joshua Myers, Son Nguyen, et al. · Gastroenterology · 2

FRI415 Patient Preference And Proof-of-concept For A Once-daily Follicle Stimulating Hormone (FSH) Biosimilar Delivered Via An Orally Ingestible Robotic Pill (RT-112)

2023 · Alyson Yamaguchi, Kyle Horlen, et al. · Journal of the Endocrine Society · 2

SAT235 An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study

2023 · Joshua T Myers, Anvesh Dasari, et al. · Journal of the Endocrine Society · 2

Works count: 6

Citation count: 53

H-index: 2

I10-index: 1